Bristol Myers Squibb is the latest large pharma company to be making a major bet on artificial intelligence, announcing a sweeping agreement with Anthropic to deploy its AI tool Claude as the “shared ...

After some six years at the post, Amgen’s finance chief is telegraphing his exit from the California pharma by early next ...

Gilead Sciences has broadened its partnership with Korean manufacturer Yuhan, agreeing to a 210 billion Korean won ($140 million) supply deal for active pharmaceutical ingredients (API) for an ...

Tarsus Pharmaceuticals has spent the past three years marketing its way out of a largely unknown but stigmatized condition: ...

BeOne Medicines has tapped former professional soccer goalkeeper Tim Howard as the face of its first major corporate campaign ...

Even as a new drug pricing specter rears its head in President Donald Trump’s “Most Favored Nation” policies, drugmakers ...

As Eli Lilly moves to set up a mammoth manufacturing facility in Houston, it’s not the only U.S. pharma juggernaut with an ...

A Novartis cross-border partnership is turning into a standoff. | A Novartis cross-border partnership is turning into a ...

Over the last 18 months, Merck and Kelun-Biotech have notched four approvals in China for their TROP2-directed antibody-drug ...

President Donald Trump earlier this year bought as much as $680,000 in stock of Eli Lilly, the maker of blockbuster obesity ...

Already tracking at $5 billion in annual sales, Enhertu has secured two new FDA approvals to treat early breast cancer. But ...

Roche has signed a voluntary license agreement providing its popular influenza antiviral drug Xofluza (baloxavir marboxil) ...